US 11,851,657 B2
Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
Guangping Gao, Westborough, MA (US); Yi Lu, Shanghai (CN); Qiang Zheng, Chengdu (CN); Xun Xu, Shanghai (CN); Phillip D. Zamore, Northborough, MA (US); and Phillip Tai, Worcester, MA (US)
Assigned to University of Massachusetts, Boston, MA (US)
Filed by University of Massachusetts, Boston, MA (US)
Filed on Jun. 9, 2021, as Appl. No. 17/342,587.
Application 17/342,587 is a continuation of application No. 16/076,881, granted, now 11,060,088, previously published as PCT/US2017/017469, filed on Feb. 10, 2017.
Claims priority of provisional application 62/294,362, filed on Feb. 12, 2016.
Prior Publication US 2021/0380981 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/04 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01); C12N 15/11 (2006.01); A61P 27/02 (2006.01); A61K 9/00 (2006.01); A61K 48/00 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61P 27/02 (2018.01); C12N 15/111 (2013.01); C12N 15/86 (2013.01); A61K 48/00 (2013.01); C12N 2310/113 (2013.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01); C12N 2330/51 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01)] 4 Claims
 
1. A recombinant adeno-associated virus (rAAV) comprising:
(i) a capsid protein having a serotype of AAVrh.10 encoded by the amino acid sequence set forth in SEQ ID NO: 14; and,
(ii) a nucleic acid comprising a promoter operably linked to a transgene encoding a protein associated with an ocular disease, wherein the transgene comprises a tough decoy (TuD) miRNA having a region of complementarity to SEQ ID NO:1.